Recent studies have indicated that combining oncolytic viruses with other therapies increases the expression of proinflammatory cytokines, including IFN-γ, which activates JAK1/2 signaling and improves antigen presentation, thereby increasing tumor sensitivity to checkpoint blockade [192, 193]. The gene discussed is IFNG; the disease is neoplasm.